About Athersys (NASDAQ:ATHX)
Athersys, Inc., a biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs are focused on treating neurological conditions, cardiovascular diseases, inflammatory and immune disorders, and pulmonary and other conditions. The company's lead platform product includes MultiStem cell therapy, an allogeneic stem cell product, which has completed Phase II study for treating patients suffering from moderate and severe ischemic stroke; that is in Phase II clinical study for treating patients with acute myocardial infarction; and, which is in Phase I/II clinical study for treating patients with acute respiratory distress syndrome, as well as that has completed Phase I clinical study for patients suffering from leukemia or various other blood-borne cancers. It also develops MultiStem cell therapy to promote tissue repair and healing for animal patients, including those suffering from serious conditions with unmet medical need. The company has license and collaboration agreements with Healios K.K. to develop and commercialize MultiStem cell therapy for ischemic stroke in Japan; RTI Surgical, Inc. to develop and commercialize biologic implants for orthopedic applications in the bone graft substitutes market; the University of Minnesota to develop MultiStem cell therapy platform; and Bristol-Myers Squibb Company to provide cell lines expressing well validated drug targets for compound screening and development. Athersys, Inc. was founded in 1995 and is headquartered in Cleveland, Ohio.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Trailing P/E Ratio-8.00
Forward P/E Ratio-9.67
Sales & Book Value
Annual Sales$3.71 million
Price / Sales86.27
Price / CashN/A
Book Value$0.20 per share
Price / Book11.60
EPS (Most Recent Fiscal Year)($0.29)
Return on Equity-119.58%
Return on Assets-92.10%
Athersys (NASDAQ:ATHX) Frequently Asked Questions
What is Athersys' stock symbol?
Athersys trades on the NASDAQ under the ticker symbol "ATHX."
How were Athersys' earnings last quarter?
Athersys, Inc. (NASDAQ:ATHX) released its quarterly earnings data on Thursday, May, 10th. The biopharmaceutical company reported ($0.08) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.09) by $0.01. The biopharmaceutical company had revenue of $1.07 million for the quarter, compared to analysts' expectations of $1.17 million. Athersys had a negative return on equity of 119.58% and a negative net margin of 1,112.74%. View Athersys' Earnings History.
When is Athersys' next earnings date?
What price target have analysts set for ATHX?
1 Wall Street analysts have issued 1 year price objectives for Athersys' stock. Their predictions range from $6.00 to $6.00. On average, they anticipate Athersys' stock price to reach $6.00 in the next year. View Analyst Ratings for Athersys.
What are Wall Street analysts saying about Athersys stock?
Here are some recent quotes from research analysts about Athersys stock:
- 1. Maxim Group analysts commented, "Athersys and the University of Texas Health Science Center at Houston (UTHealth) announced plans to initiate a P2 study of MultiStem for the treatment and prevention of complications after severe traumatic injury. $3.5M in grant funding will be used to support the study." (4/23/2018)
- 2. According to Zacks Investment Research, "Athersys is a biopharmaceutical company engaged in the discovery and development of therapeutic product candidates designed to extend and enhance the quality of human life. The company's lead product candidate, ATHX-105, is an oral, selective 5HT2c receptor agonist in Phase I clinical trials for the treatment of obesity. The company is also developing other orally active pharmaceutical product candidates for the treatment of metabolic and central nervous system disorders, utilizing proprietary technologies, including Random Activation of Gene Expression (RAGE). Athersys is developing MultiStem(r), its patented, adult-derived ``off the shelf'' stem cell product platform, for multiple disease indications, including damage caused by myocardial infarction, bone marrow transplantation/oncology support, ischemic stroke and other indications. " (4/18/2018)
Who are some of Athersys' key competitors?
Some companies that are related to Athersys include Apellis Pharmaceuticals (APLS), Zai Lab (ZLAB), Alder Biopharmaceuticals (ALDR), Athenex (ATNX), Revance Therapeutics (RVNC), Retrophin (RTRX), Intra-Cellular Therapies (ITCI), Eagle Pharmaceuticals (EGRX), Esperion Therapeutics (ESPR), TG Therapeutics Inc common stock (TGTX), Epizyme (EPZM), Reata Pharmaceuticals (RETA), Dynavax Technologies (DVAX), Endocyte (ECYT) and Flexion Therapeutics (FLXN).
Who are Athersys' key executives?
Athersys' management team includes the folowing people:
- Dr. Gil Van Bokkelen, Co-Founder, Chairman & CEO (Age 57)
- Mr. William B. J. Lehmann Jr., Pres, COO & Sec. (Age 52)
- Dr. John J. Harrington, Co-Founder, Chief Scientific Officer, Exec. VP & Director (Age 51)
- Ms. Laura K. Campbell, Sr. VP of Fin. (Age 54)
- Dr. Manal Morsy M.D., PH.D., Sr. VP & Head of Global Regulatory Affairs
Has Athersys been receiving favorable news coverage?
Media headlines about ATHX stock have trended somewhat positive on Monday, according to Accern. The research firm identifies negative and positive media coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Athersys earned a news sentiment score of 0.15 on Accern's scale. They also gave media coverage about the biopharmaceutical company an impact score of 46.31 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company's share price in the next few days.
Who are Athersys' major shareholders?
Athersys' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (3.55%), Northern Trust Corp (0.88%), Blair William & Co. IL (0.07%) and JPMorgan Chase & Co. (0.05%). Company insiders that own Athersys stock include Ismail Kola, John J Harrington, Laura K Campbell and William Lehmann Jr. View Institutional Ownership Trends for Athersys.
Which major investors are selling Athersys stock?
ATHX stock was sold by a variety of institutional investors in the last quarter, including Blair William & Co. IL and BlackRock Inc.. Company insiders that have sold Athersys company stock in the last year include John J Harrington and William Lehmann Jr. View Insider Buying and Selling for Athersys.
Which major investors are buying Athersys stock?
ATHX stock was acquired by a variety of institutional investors in the last quarter, including Northern Trust Corp and JPMorgan Chase & Co.. Company insiders that have bought Athersys stock in the last two years include Ismail Kola and Laura K Campbell. View Insider Buying and Selling for Athersys.
How do I buy shares of Athersys?
Shares of ATHX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Athersys' stock price today?
One share of ATHX stock can currently be purchased for approximately $2.32.
How big of a company is Athersys?
Athersys has a market capitalization of $320.06 million and generates $3.71 million in revenue each year. The biopharmaceutical company earns $-32,240,000.00 in net income (profit) each year or ($0.29) on an earnings per share basis. Athersys employs 66 workers across the globe.
How can I contact Athersys?
Athersys' mailing address is 3201 CARNEGIE AVENUE, CLEVELAND OH, 44115. The biopharmaceutical company can be reached via phone at 216-431-9900 or via email at [email protected]
MarketBeat Community Rating for Athersys (ATHX)MarketBeat's community ratings are surveys of what our community members think about Athersys and other stocks. Vote "Outperform" if you believe ATHX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ATHX will underperform the S&P 500 over the long term. You may vote once every thirty days.